ABSTRACT
Continuous-variable quantum key distribution (CV-QKD) is a promising protocol that can be easily integrated with classical optical communication systems. However, in the case of quantum-classical co-transmissions, such as dense wavelength division multiplexing with classical channels and time division multiplexing with large-power classical signal, a quantum signal is more susceptible to crosstalk caused by a classical signal, leading to signal distortion and key distribution performance reduction. To address this issue, we propose a noise-suppression scheme based on carrier frequency switching (CFS) that can effectively mitigate the influence of large-power random noise on the weak coherent state. In this noise-suppression scheme, a minimum-value window of the channel's noise power spectrum is searched for and the transmission signal frequency spectrum shifts to the corresponding frequency to avoid large-power channel noise. A digital filter is also utilized to filter out most of the channel noise. Simulation results show that compared to the traditional fixed carrier frequency scheme, the proposed noise-suppression scheme can reduce the excess noise to 1.8%, and the secret key rate can be increased by 1.43 to 2.86 times at different distances. This noise-suppression scheme is expected to be applied in scenarios like quantum-classical co-transmission and multi-QKD co-transmission to provide noise-suppression solutions.
ABSTRACT
Brivanib Alaninate is a novel chiral prodrug possessing two stereogenic centers. Simultaneous HPLC separation of five isomers of Brivanib Alaninate was systematically investigated on a wide variety of polysaccharide-based chiral stationary phases (CSPs) using underivatization and pre-column derivatization methods. The influence of derivatizing groups and mobile phase composition on the enantioseparation and retention behavior of Brivanib Alaninate compounds was studied. To better understand the chiral recognition mechanism, the temperature effect was also evaluated. The results of these studies led to the first complete HPLC resolution of all five isomers of Brivanib Alaninate as carbobenzyloxy (CBZ) derivatives on a cellulose benzoate CSP (OJ-H).
Subject(s)
Alanine/analogs & derivatives , Chromatography, High Pressure Liquid/methods , Triazines/isolation & purification , Alanine/isolation & purification , Polysaccharides/chemistry , Stereoisomerism , TemperatureABSTRACT
Substituted biphenyl I (BMS-207940), a selective antagonist of the endothelin A (ETA) receptor, has been proposed for the treatment of congestive heart failure. The structure of I possesses a stereogenic axis due to the hindered rotation about the biphenyl bond in the presence of its large ortho-substituents. As a result, I exhibits atropisomerism in which two nonplanar, axially enantiomers exist, which will be generically referred to as isomers A and B. Within the pharmaceutical industry, both from a scientific and regulatory point of view, characterization of enantiomeric drugs has become an important step in the development process. To investigate the configurational stability of I atropisomers, normal phase enantiomeric LC with tandem UV and laser polarimetric detection was used under pseudo-physiological conditions: first in a simple aqueous medium at 37 degrees C, and then in human serum at 37 degrees C. Kinetic studies indicated that the half-life of I enantiomerization in an aqueous medium at 37 degrees C was ca. 15 h. Enantiomerization of I atropisomers was greatly accelerated in the presence of human serum and human serum albumin, and the rate of enantiomerization depended on the concentration of I. The sera-concentration-dependent enantiomerization behavior of I strongly suggests a restricted site-specific substrate/I interaction mechanism. It was therefore demonstrated that atropisomeric interconversion studies for the compound studied required consideration of temperature, presence of plasma proteins, and drug concentration to account for the kinetic data.
